J&J Transitions to New CEO
Johnson & Johnson announced that Alex Gorsky, CEO for the past decade, is stepping down from his position and will be replaced by Joaquin Duato effective January 3rd. Gorsky is leaving his position due to “family health reasons,” but will remain as a Vice Chairman on the Executive Committee.
Duato has been at the company for over 30 years and was a hands-on leader during the pandemic push, overseeing “the company’s rapid response to the COVID-19 pandemic and led coordination of global initiatives to safeguard the health of employees and ensure business and supply chain continuity,” according to a J&J press release. Duato was previously working with the Consumer Health leadership and driving growth and profits of its $60 billion portfolio. He stated, “As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health.”
The leading full-service contract development and manufacturing organization appointed Sally Langa as its new Global SVP Sales and Marketing to help drive the company’s continued growth and achieve its aggressive expansion plans. With a track record for delivering diverse and profitable growth, Langa will help the company meet its ambitious growth targets globally, as well as optimize the company’s Sales and Marketing function in her leadership role.
The independent agency announced that its Chief Creative Officer, Steve Hamburg, will now serve as Chief Strategy Officer. A strategy stickler, Hamburg kept up his strategic rigor even after transitioning from brand strategy for large-scale consumer clients to creative and healthcare/pharma. He will now focus on making Calcium’s brand strategy expertise even more robust and relevant by marshalling his unique skills, vision, and experience to more fully nourish current clients and brands.
CMI Media Group and Compas
The leading media agency and certified diverse supplier appointed Oleg Korenfeld as their new Chief Technology Officer. With over 20 years of marketing data and technology experience on the global scale, Korenfeld will be responsible for building the future vision of the intersection of media, data, and technology for the companies and their clients.
The California-based company focused on therapies personalized to each patient’s biology has added several prominent leaders to their strategic counsel, including Merdad Parsey, MD, Chief Medical Officer of Gilead. The company will draw on Dr. Parsey’s expertise from spearheading Gilead’s global clinical development and medical affairs organizations, including the supervision of all clinical trials and development operations.
The global independent marketing and communications firm added three new leaders, including Pepe Aguilar as Executive Creative Director; Richard Hatzfeld as Senior Partner, Global Health; and Ritesh Patel as Senior Partner, Global Digital Health. Aguilar joins FINN from his previous role as Chief Creative Officer of Grey Wing New York, where he achieved record-breaking revenues and a slew of top-tier award wins. Hatzfeld will lead FINN’s DC Health Group efforts backed by his experience working in Africa, Asia, Europe, and North America on behalf of governments, multinational companies, foundations, and NGOs. Patel joins from Ogilvy Consulting and is known to be a health-technology visionary who has led the move for digital transformation throughout the industry.
The full-service healthcare communications agency that is part of Syneos Health Communications added three executive leaders to their team, including Jim Ruiz as SVP, Customer Experience, MarTech Strategy & Enablement Lead. Ruiz, who is joining from Intouch Solutions, brings 20 years of experience in developing and delivering multichannel and omnichannel customer experiences, which gives him a unique perspective on pharma marketing and managing cross-functional teams.
Aamir Malik joined the company as Executive Vice President and Chief Business Innovation Officer. Previously at McKinsey & Company, he will oversee Pfizer’s strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures.